-
On Jan. 29, 2009, the Food and Drug Administration (FDA) approved revisions to the lopinavir/ritonavir (Kaletra®) package insert to include drug-drug interaction information for concurrent lopinavir/ritonavir administration with inhaled medicines such as salmeterol or salmeterol in combination with fluticasone propionate (Serevent®, Advair®) and sildenafil (Revatio®).
-
Frailty is not a diagnosis that typically comes to mind when clinicians examine HIV patients, but with increasing numbers of older people being diagnosed or younger patients growing old with the disease, it should be on HIV clinicians' radar.
-
AIDS-defining conditions and risks are different for HIV-positive patients who are older, usually defined as age 50 and above, experts say.
-
An estimated 430,000 children worldwide became infected with HIV in 2008, mostly through birth or breastfeeding from an HIV-infected mother.
-
-
Review board mission creep: nearly every research organization experiences it, and most clinical trial sites resent it.
-
Research sites can improve the way they handle regulatory requirements and encourage more investigators to conduct research by making simple changes, an expert says.
-
It might seem too daring to make changes to human subjects oversight programs by easing ethics review procedures. But several research organizations have found that some measured changes can help reduce investigators' regulatory burden without increasing risk to subjects.
-
Increasing numbers of research institutions have opened offices to provide oversight of investigator-initiated clinical trials, but they often lack the basic tools needed for this process.
-
The University of Pittsburgh in Pittsburgh, PA, has developed a thorough, review process that serves as an educational opportunity, as well as a way to prevent clinical research problems.
